Results 41 to 50 of about 10,001 (276)

Reversal of hepatorenal syndrome in cirrhotic patients with terlipressin plus albumin. First experience in Mexico

Annals of Hepatology, 2009
Introduction. Type 1 hepatorenal syndrome (HRS) is a functional renal failure that complicates end-stage cirrhosis. The vasopressin analogue terlipressin has been associated with improved renal function in patients with type 1 HRS.Aim.
Linda E. Muñoz, Eliud G. Alcalá, Paula Cordero, Manuel A. Martinez, Nathalie Y. Vázquez, Susana Galindo, Eduardo Mendoza, José J. Segura   +7 more
doaj   +1 more source

Vasopressin and Terlipressin in the Treatment of Vasodilatory Septic Shock: A Systematic Review

Proceedings of Singapore Healthcare, 2011
Background: Vasodilatory septic shock unresponsive to fluid resuscitation requires the addition of vasopressors. Catecholamines remain the first line vasopressor therapy, but treatment failure is a potential problem.
Jie Lin Soong BSc (Pharm) (Hons), Wai Hing Lim B Pharm (Hons), M Clin Pharm   +1 more
doaj   +1 more source

Terlipressin-induced hyponatremic encephalopathy in a noncirrhotic patient

Kaohsiung Journal of Medical Sciences, 2013
Terlipressin, an analogue of vasopressin, is frequently used for the management of esophageal varices bleeding and hepatorenal syndrome. Terlipressin therapy in portal hypertensive patients is frequently associated with hyponatremia, but is rarely ...
Yao-Kuang Wang, Daw-Yang Hwang, Sophie S.W. Wang, Shang-Jyh Hwang, Li-Tzong Chen, Mei-Chuan Kuo   +5 more
doaj   +1 more source

INFUSE: Rationale and design of a multi-center, open label, collaborative study to treat HRS-AKI with continuous terlipressin infusion

Contemporary Clinical Trials Communications, 2023
Background: Hepatorenal syndrome-acute kidney injury (HRS-AKI) carries significant morbidity and mortality among those with end-stage liver disease. Bolus terlipressin for treatment of HRS-AKI received FDA approval in September 2022. US implementation of
Ethan Weinberg, Suditi Rahematpura, Stevan A. Gonzalez, Manhal J. Izzy, Douglas A. Simonetto, R. Todd Frederick, Raymond A. Rubin, Jade Ikahihifo-Bender, Maggie Harte, Grace Kim-Lee, Sherry Witkiewicz, William Tobin, Khurram Jamil, Zachary Fricker, K. Rajender Reddy   +14 more
doaj   +1 more source

Hemodynamic profile of terlipressin and octreotide in patients with cirrhosis and portal hypertension: a randomized, single-blind clinical trial. [PDF]

JHEP Rep
Perez-Campuzano V, Olivas P, Ferrusquía-Acosta J, Torres S, Borras R, Baiges A, Orts L, Vizcarra P, Falga MA, Codina J, Shalaby S, Ojeda A, Turon F, Hernández-Gea V, Cárdenas A, García-Pagán JC.   +15 more
europepmc   +2 more sources

Initial serum sodium concentration determines the decrease in sodium level after terlipressin administration in patients with liver cirrhosis [PDF]

, 2013
BACKGROUND: Terlipressin, as a prodrug of vasopressin, has agonistic effects on the V1 receptor and partial agonistic effects on renal vasopressin V2 receptors. However, its effects on serum sodium concentration are controversial.
Dae-Hong Jeon, Dong Park, Eun Bae, Ha Jang, Hyun Cho, Kyungo Hwang, Se-Ho Chang, Yeo-Jin Kang   +7 more
core   +1 more source

Safety, Tolerability, Pharmacokinetics, and Efficacy of Terlipressin Delivered by Continuous Intravenous Infusion in Patients with Cirrhosis and Refractory Ascites

GastroHep, 2022
Background. Terlipressin is a long acting synthetic analogue of vasopressin, which is used to manage variceal bleeding and hepatorenal syndrome.
Jasmohan S. Bajaj, James H. Fischer, Patrick Yeramian, Edith A. Gavis, Andrew Fagan, Paolo Angeli, Guadalupe Garcia-Tsao, Jonathan M. Adams, Penelope Markham   +8 more
doaj   +1 more source

Incidence and type of adverse events in patients with cirrhosis receiving terlipressin: A systematic review and meta-analysis. [PDF]

Hepatol Commun
Background: Terlipressin has been widely used for various cirrhosis-related complications, but its safety profile remains controversial. Herein, this issue was systematically evaluated.
Shang Y, Wang C, Lu H, Chai L, Xu W, Bernardi M, Qi X.   +6 more
europepmc   +2 more sources

Protection of cerebral microcirculation, mitochondrial function and electrocortical activity by small-volume resuscitation with terlipressin in a model of haemorrhagic shock [PDF]

, 2017
Background During early treatment of haemorrhagic shock, cerebral perfusion pressure can be restored by small-volume resuscitation with vasopressors. Whether this therapy is improved with additional fluid remains unknown.
Chisholm, KI, Duchen, MR, Dyson, A, Ida, KK, Malbouisson, LMS, Papkovsky, DB, Singer, M, Smith, KJ   +7 more
core   +1 more source

Terlipressin Induced Severe Hyponatremia

Prague Medical Report, 2016
Terlipressin is a vasopressin analogue used for its vasoconstrictor effect in the treatment of variceal bleeding. Despite its good safety profile compared to vasopressin, some adverse reactions may occur during its use – e.g. hyponatremia.
Martin Šíma, Miroslav Pokorný, František Paďour, Ondřej Slanař   +3 more
doaj   +1 more source